Tags

Type your tag names separated by a space and hit enter

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.
Aliment Pharmacol Ther. 2004 Jul 01; 20(1):23-8.AP

Abstract

BACKGROUND

Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease.

AIM

A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease.

METHODS

In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology.

RESULTS

Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis.

CONCLUSION

Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Authors+Show Affiliations

Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA. snair@ochsner.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15225167

Citation

Nair, S, et al. "Metformin in the Treatment of Non-alcoholic Steatohepatitis: a Pilot Open Label Trial." Alimentary Pharmacology & Therapeutics, vol. 20, no. 1, 2004, pp. 23-8.
Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20(1):23-8.
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004). Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology & Therapeutics, 20(1), 23-8.
Nair S, et al. Metformin in the Treatment of Non-alcoholic Steatohepatitis: a Pilot Open Label Trial. Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8. PubMed PMID: 15225167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. AU - Nair,S, AU - Diehl,A M, AU - Wiseman,M, AU - Farr,G H,Jr AU - Perrillo,R P, PY - 2004/7/1/pubmed PY - 2004/11/2/medline PY - 2004/7/1/entrez SP - 23 EP - 8 JF - Alimentary pharmacology & therapeutics JO - Aliment Pharmacol Ther VL - 20 IS - 1 N2 - BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/15225167/Metformin_in_the_treatment_of_non_alcoholic_steatohepatitis:_a_pilot_open_label_trial_ L2 - https://doi.org/10.1111/j.1365-2036.2004.02025.x DB - PRIME DP - Unbound Medicine ER -